Search
Desloratadine
go.drugbank.com/drugs/DB00967ApprovedInvestigationalDesloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system. … It is the active descarboethoxy metabolite of loratidine (a second generation histamine).
Mixtures: AIRCOMB 2,5 MG/4 MG GRANÜL İÇEREN SAŞE, 30 ADET, AIRCOMB 2,5 MG/4 MG GRANÜL İÇEREN SAŞE, 90 ADETCategories: Antihistamines for Systemic Use, Histamine H1 Antagonists, Non-SedatingCerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency. … [L51329] CLN2 is a predominantly pediatric-onset neurodegenerative disease caused by a deficiency in the lysosomal enzyme TPP1, leading to progressive impairment in motor and cognitive function.
Synonyms: Immature tripeptidyl-peptidase ICategories: Hydrolytic Lysosomal N-terminal Tripeptidyl PeptidaseLymecycline
go.drugbank.com/drugs/DB00256ApprovedInvestigationalWithdrawnIt is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. … Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections.
Synonyms: N-Lysinomethyltetracycline, (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamideCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseSipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalIt must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). … Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer.
Pancreatic Metastatic Cancer
go.drugbank.com/conditions/DBCOND0070216Synonyms: Secondary malignant deposit in pancreasCangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalCangrelor was approved by the FDA in June 2015 for intravenous application. … Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.
Levallorphan
go.drugbank.com/drugs/DB00504ApprovedAn opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties. … It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants
Categories: Heterocyclic Compounds with 4 or More RingsTazemetostat
go.drugbank.com/drugs/DB12887ApprovedInvestigationalTazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. … [L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476]
Categories: MATE 2-K InhibitorsDimethyl fumarate
go.drugbank.com/drugs/DB08908ApprovedInvestigational[A253917] Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis.[A253917] … in response to oxidative stress.
Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigational[L46342,L46387] Later on, the FDA approved pegunigalsidase alfa for the treatment of adult patients with Fabry disease that same month.[L46432,L46437] … Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized